Knight Capital Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Knight Capital Group’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$1.08M	Buy	+101,938	New	+$1.19M	0.02%	946

Other funds holding CTIC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Knight Capital Group's CTIC Position: Q2 2013 in Review

Knight Capital Group opened a new position in CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2013: 101,938 shares worth $1.08M. The stake represents 0.02% of the portfolio and ranks #946 among its holdings.

64 funds tracked by Wall St. Rank hold CTIC as of Q2 2013.

Knight Capital Group held 101,938 shares of CTI BioPharma Corp. (DE) Common Stock worth $1.08M as of Q2 2013.
CTI BioPharma Corp. (DE) Common Stock was a new Knight Capital Group position in Q2 2013.
CTI BioPharma Corp. (DE) Common Stock made up 0.02% of Knight Capital Group's portfolio in Q2 2013, its #946 holding.
64 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.